
GSK's blood cancer drug gets EU approval
The Hindu
EU approves GSK's Blenrep for relapsed multiple myeloma, showing improved survival rates in phase III trials.
More Related News

EU approves GSK's Blenrep for relapsed multiple myeloma, showing improved survival rates in phase III trials.